-A success made possible by an exclusive pharmacy
 contract in China

-Plans for further success in China through local strategies

Daewoong Pharmaceutical Co., Ltd., with their hit item, URSA, has sold nearly 0.1 million boxes in two months in China. URSA was registered in China’s health insurance independently, a first in this field. China has acknowledged the superiority of URSA. Daewoong Pharmaceutical Co., Ltd., based on their outstanding product efficiency, has passed China’s bid last December.

Daewoong Pharmaceutical Co., Ltd., with their sales of URSA, plans to launch their marketing, which promises to be of variety and seriousness. Daewoong Pharmaceutical Co., Ltd. already has established a research facility in year of 2008 at China for a global R&D system infrastructure. Last year this corporation has completed the registration of, other than URSA, 5 products including antibiotics and is in the process of adding 16 more to the list.

China>

The market for medicine in China is about 30 trillion won according to 2008 standards, and averages about 16% in growth after 2000. Further increase in these numbers is expected due to the expected growth of health insurance and health care. However, this market is not considered an easy one for foreign corporations. In a study done in 2008, almost all but one of the top 20 pharmaceutical companies was local, the exception being Bayer, ranked at 10^th. And also, Daewoong Pharmaceutical Co., Ltd. tends to acquire the necessary human resources, infrastructure, and research to formulate their steady business in China.

Daewoong Pharmaceutical Co., Ltd. boldly hired the necessary people to do the job, graduates of China’s prestigious universities, as well as talented characters from China’s pharmaceutical companies. And, they also plan to distribute incentives according to talent, and a chance to encounter the same experiences as they can at headquarters.

Daewoong Pharmaceutical Co., Ltd., based on their headquarters in China, along with local universities and research corporations, plans to construct a state of the art R&D center and later a factory in order to manufacture the best medicine they can. They also plan to build close ties with local corporations for efficient circulation of their products

1.      URSA

China has a market of liver-related diseases that cost up to 600 billion won (2007 standard), among this ratio, 8 percent of this figure is related with bile diseases. URSA, unlike any other products in the market, is a soft-capsule product. Daewoong also hopes to relate their company mascot, the bear, and China’s national emblem, the panda together to create a sense of affinity that will help the company.

2.      Bearse, Newlanta

Digestive-related pharmaceutical market in China has a value of nearly 4.6 trillion won, and within this market, digestive enzymes mark a figure of about 127 billion won. Daewoong’s number one digestive enzyme, Bearse, plans to commercialize itself in China by appealing to the fact that it suits the Chinese’s diet of high oil. Newlanta has one of the Chinese’s favorite tastes; orange, and has a high compliance rate that seeks to empower the efficiency of the drug. An antacid in China has a market value of about 110 billion won. Newlanta has no constipation side effects, is harmless to patients with diabetes or high blood pressure. It also quickly raises the pH of the body and maintains a high pH within the body.